Pharmaceutical compositions comprising a compound according to General formula (1) and the use of such compounds for the treatment of various conditions such as conditions for Positive and negative symptoms of schizophrenia, as well as Cognitive alterations Associated Das with schizophrenia, Alzheimer's disease and other Neurological and Psychiatric Disorders.The compounds of the present are inhibitory Properties of Glycine TRANSPORTER 1 (giyt1).Claim 1: a compound characterized by the General formula (1) wherein R1 is selected from the group of monocyclic heteroaryl) 5 or 6 members, which has 1, 2, 3 or 4 heteroatoms selected independently, Group o, N and S (R, b) heterocicloalquilo) Partially saturated monocyclic 5 or 6 members, have 1, 2 or 3 heteroatoms selectedIndependently, Group o, N and S (R), and (c) bicyclic heteroaryl 9 or 10 members, have 1, 2 or 3 heteroatoms selected independently, Group o, N and S (o) R, where r is 0, 1 or 2 where each group (a), (b) and (c) optionally Sustituid Or with 1 or more substituents selected independently, c1-4 alkyl group.C1-4 alkyl - or - oxetanilo, tetrahidrofuranilo, tetrahidropiranilo cycloalkyl, C3 and C3 cicloalquil - 6 - 6 - or - in the case of a Substituent is attached to a nitrogen Atom in the ring, the Substituent is selected from the group of c1-4 alkyl c1-4 alkyl -, co -, C3 and cicloal cycloalkyl - 6 - Quil C3 - 6 - CO, and where each of these substituents c1-4 alkyl, c1-4 alkyl - or -C1-4 alkyl co, oxetanilo, tetrahidrofuranilo, tetrahidropiranilo cicloalquil C3 -, 6 -, cicloalquil C3 - 6 - CO - or cicloalquil C3 - 6 - or - may be substituted with one or more substituents selected independently of the fluoro - Cf3 Group, CHF2 CH2f, -, - and - CN； R2 is selected from the Group Hydrogen, c1-4 alkyl, alkyl - or - C1 - 4, - cn and cicloalquil C3 - 6 -Where each of these alkyl groups c1-4 alkyl -, 4 - or - C1 - C3 - and cicloalquil 6 - can be optionally replaced with 1, 2, 3 or more substituents selected independen
